3rd Circuit Revives Fosamax MDL Over Questions of Preemption
The decision, which the U.S. Court of Appeals for the Third Circuit said was a "close call," hinged on whether an informal communication in the form of a letter the FDA sent to Merck was sufficient to establish preemption.
September 23, 2024 at 03:27 PM
4 minute read
PharmaceuticalsThe U.S. Court of Appeals for the Third Circuit has rejected arguments that the plaintiffs' claims in the Fosamax litigation should be preempted by U.S. Food and Drug Administration regulations.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View AllBristol-Myers Squibb Wins Dismissal of $6.4 Billion Lawsuit Alleging Intentional Delay of Cancer Drug
Drugmaker Accused of Overhyping Proposed COVID Treatment Agrees to $3M Settlement
4 minute readPharma Company Raises Patent Infringement Allegations Over Generic Version of Narcolepsy Treatment
Who Got the Work: Saul Ewing Team Appears for Samsung Bioepis in Amgen Patent Case
4 minute readLaw Firms Mentioned
Trending Stories
- 1The Law Firm Disrupted: Playing the Talent Game to Win
- 2A&O Shearman Adopts 3-Level Lockstep Pay Model Amid Shift to All-Equity Partnership
- 3Preparing Your Law Firm for 2025: Smart Ways to Embrace AI & Other Technologies
- 4BD Settles Thousands of Bard Hernia Mesh Lawsuits
- 5A RICO Surge Is Underway: Here's How the Allstate Push Might Play Out
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250